"Epoetin Alfa" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A recombinant glycosylated form of erythropoietin which stimulates the differentiation and proliferation of erythroid precursors. It is used for the treatment of ANEMIA associated with CHRONIC RENAL FAILURE in dialysis and predialysis patients.
| Descriptor ID |
D000068817
|
| MeSH Number(s) |
D12.644.276.374.410.240.150.500 D12.776.395.240.150.750 D12.776.467.374.410.240.150.500 D23.529.374.410.240.150.750
|
| Concept/Terms |
Epoetin Alfa- Epoetin Alfa
- Alfa, Epoetin
- Recombinant 1-165 Erythropoietin, Glycoform Alpha
- Recombinant 1 165 Erythropoietin, Glycoform Alpha
|
Below are MeSH descriptors whose meaning is more general than "Epoetin Alfa".
Below are MeSH descriptors whose meaning is more specific than "Epoetin Alfa".
This graph shows the total number of publications written about "Epoetin Alfa" by people in this website by year, and whether "Epoetin Alfa" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 3 | 3 |
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 3 | 3 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Epoetin Alfa" by people in Profiles.
-
The First 2?Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions. Oncologist. 2021 08; 26(8):e1418-e1426.
-
Investigating Serious Adverse Drug Reactions in Patients Receiving Erythropoiesis-Stimulating Agents: A Root Cause Analysis Using the "ANTICIPATE" Framework. Am J Ther. 2018 Nov/Dec; 25(6):e670-e674.
-
RAS modulation prevents progressive cognitive impairment after experimental stroke: a randomized, blinded preclinical trial. J Neuroinflammation. 2018 Aug 13; 15(1):229.
-
Minimizing Blood Loss and Transfusions in Total Knee Arthroplasty. J Knee Surg. 2018 Aug; 31(7):594-599.
-
Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia. J Oncol Pract. 2017 06; 13(6):e562-e573.
-
Emerging drugs for treatment of anemia of chronic kidney disease. Expert Opin Emerg Drugs. 2013 Dec; 18(4):421-9.
-
Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial. Am Heart J. 2010 Nov; 160(5):795-803.e2.
-
Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion. 2008 Aug; 48(8):1754-62.
-
Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol. 2008 Jan 01; 26(1):132-49.
-
Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood. 2008 Jan 01; 111(1):25-41.